Publication:
Raveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)

Simple item page
dc.contributor.authorsBircan K., Özen H.A., Ergen A., Başar I., Özgür S., Ilker Y., Karaaĝaoĝlu E., Remzi D.
dc.date.accessioned2022-03-15T01:47:48Z
dc.date.accessioned2026-01-11T10:27:55Z
dc.date.available2022-03-15T01:47:48Z
dc.date.issued1990
dc.description.abstractThirty patients with BPH were randomized into two groups to receive Raveron® and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron® and placebo. © 1990 Akadémiai Kiadó.
dc.identifier.doi10.1007/BF02549794
dc.identifier.issn3011623
dc.identifier.pubmed1699907
dc.identifier.urihttps://hdl.handle.net/11424/246182
dc.language.isoeng
dc.publisherKluwer Academic Publishers
dc.relation.ispartofInternational Urology and Nephrology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleRaveron® versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH)
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage348
oaire.citation.issue4
oaire.citation.startPage345
oaire.citation.titleInternational Urology and Nephrology
oaire.citation.volume22

Files

Collections

Araştırma Çıktıları